Dr. Sigsbee W Duck, MD Otolaryngology - Otolaryngic Allergy Medicare: Accepting Medicare Assignments Practice Location: 1180 College Dr, Rock Springs, WY 82901 Phone: 307-212-7738 Fax: 307-212-7786 |
Ms. Cheryl Lynn Varner, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1333 W 5th St, Ste 206, Sheridan, WY 82801 Phone: 307-675-4646 Fax: 307-675-4645 |
Dr. Scott N Bateman, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 330 W Dow St, Sheridan, WY 82801 Phone: 307-672-0290 Fax: 307-672-0884 |
News Archive
The ability to recognize visually presented objects relies on a critical neural pathway called the ventral stream. Previous imaging studies of the human brain have demonstrated that the sight of nonliving objects, such as tools and houses, activates different regions within the ventral stream than the sight of living things, such as animals and faces. It is not known whether category-specific neural responses in the ventral stream depend on visual experience.
Advancing the development of novel methods for understanding gene expression, Integrated DNA Technologies has enabled Dr Jim Hughes, Associate Professor at the Weatherall Institute of Molecular Medicine, Oxford, UK, to optimize his unique Capture-C method, based on Chromosomal Conformational Capture (3C).
Youth who are going to develop psychosis can be identified before their illness becomes full-blown 35 percent of the time if they meet widely accepted criteria for risk, but that figure rises to 65 to 80 percent if they have certain combinations of risk factors, the largest study of its kind has shown.
According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the emerging market for neurovascular embolectomy devices for the treatment of acute ischemic stroke is poised for healthy yet conservative growth of close to 15% annually in Europe over the next 5 years.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the first quarter ended March 31, 2010.
› Verified 1 days ago